Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions.
Abdulrahman Z, Hendriks N, J Kruse A, Somarakis A, J M van de Sande A, J van Beekhuizen H, M J Piek J, de Miranda NFCC, Kooreman LFS, F M Slangen B, van der Burg SH, de Vos van Steenwijk PJ, van Esch EMG. Abdulrahman Z, et al. Among authors: de vos van steenwijk pj. J Immunother Cancer. 2022 Nov;10(11):e005288. doi: 10.1136/jitc-2022-005288. J Immunother Cancer. 2022. PMID: 36323430 Free PMC article.
Topical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasia (TOPIC-3): A Nonrandomized Multicenter Study.
Hendriks N, Koeneman MM, van de Sande AJM, Penders CGJ, Piek JMJ, Kooreman LFS, van Kuijk SMJ, Hoosemans L, Sep SJS, de Vos Van Steenwijk PJ, van Beekhuizen HJ, Slangen BFM, Nijman HW, Kruitwagen RFPM, Kruse AJ. Hendriks N, et al. Among authors: de vos van steenwijk pj. J Immunother. 2022 Apr 1;45(3):180-186. doi: 10.1097/CJI.0000000000000414. J Immunother. 2022. PMID: 35180719 Free PMC article. Clinical Trial.
Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma.
de Vos van Steenwijk PJ, Ramwadhdoebe TH, Goedemans R, Doorduijn EM, van Ham JJ, Gorter A, van Hall T, Kuijjer ML, van Poelgeest MI, van der Burg SH, Jordanova ES. de Vos van Steenwijk PJ, et al. Among authors: van ham jj, van hall t, van der burg sh, van poelgeest mi. Int J Cancer. 2013 Dec 15;133(12):2884-94. doi: 10.1002/ijc.28309. Epub 2013 Jul 5. Int J Cancer. 2013. PMID: 23740735
Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions.
Speetjens FM, Welters MJP, Slingerland M, van Poelgeest MIE, de Vos van Steenwijk PJ, Roozen I, Boekestijn S, Loof NM, Zom GG, Valentijn ARPM, Krebber WJ, Meeuwenoord NJ, Janssen CAH, Melief CJM, van der Marel GA, Filippov DV, van der Burg SH, Gelderblom H, Ossendorp F. Speetjens FM, et al. Among authors: de vos van steenwijk pj. J Immunother Cancer. 2022 Oct;10(10):e005016. doi: 10.1136/jitc-2022-005016. J Immunother Cancer. 2022. PMID: 36261215 Free PMC article. Clinical Trial.
Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response.
de Vos van Steenwijk PJ, Piersma SJ, Welters MJ, van der Hulst JM, Fleuren G, Hellebrekers BW, Kenter GG, van der Burg SH. de Vos van Steenwijk PJ, et al. Among authors: van der hulst jm, van der burg sh. Clin Cancer Res. 2008 Nov 15;14(22):7188-95. doi: 10.1158/1078-0432.CCR-08-0994. Clin Cancer Res. 2008. PMID: 19010835
Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study.
Schuurman TN, Schaafsma M, To KH, Verhoef VMJ, Sikorska K, Siebers AG, Wenzel HHB, Bleeker MCG, Roes EM, Zweemer RP, de Vos van Steenwijk PJ, Yigit R, Beltman JJ, Zusterzeel PLM, Lok CAR, Bekkers RLM, Mom CH, van Trommel NE. Schuurman TN, et al. Among authors: de vos van steenwijk pj. Lancet Oncol. 2023 Dec;24(12):1349-1358. doi: 10.1016/S1470-2045(23)00467-9. Epub 2023 Nov 9. Lancet Oncol. 2023. PMID: 37952541
26 results